Profile
Alfredo Zurlo served as Co-Managing Director at Glycotope GmbH.
He then worked as Chief Medical Officer at MOLOGEN AG from 2013 to 2016.
After that, he served as Chief Medical Officer at Scandion Oncology A.
Zurlo holds a doctorate degree from The American University of Rome.
Former positions of Alfredo Zurlo
| Companies | Position | End |
|---|---|---|
| MOLOGEN AG | Chief Tech/Sci/R&D Officer | 31/03/2016 |
| SCANDION ONCOLOGY A/S | Chief Tech/Sci/R&D Officer | - |
Glycotope GmbH
 Glycotope GmbH BiotechnologyHealth Technology Glycotope GmbH operates as a biotechnology company to develop pharmaceutical therapeutics and nutrition additives. It focuses on the optimization and humanization of therapeutically relevant sugar structures on biopharmaceuticals known as glycosylation and on the development of innovative antibodies targeting glycostructures on cell surfaces. The company was founded by Steffen Goletz and Andreas Eckert in Febraury 2001 and is headquartered in Berlin, Germany. | Chief Executive Officer | - |
Training of Alfredo Zurlo
| The American University of Rome | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| MOLOGEN AG | Commercial Services |
| SCANDION ONCOLOGY A/S | Health Technology |
| Private companies | 1 |
|---|---|
Glycotope GmbH
Glycotope GmbH BiotechnologyHealth Technology Glycotope GmbH operates as a biotechnology company to develop pharmaceutical therapeutics and nutrition additives. It focuses on the optimization and humanization of therapeutically relevant sugar structures on biopharmaceuticals known as glycosylation and on the development of innovative antibodies targeting glycostructures on cell surfaces. The company was founded by Steffen Goletz and Andreas Eckert in Febraury 2001 and is headquartered in Berlin, Germany. | Health Technology |
- Stock Market
- Insiders
- Alfredo Zurlo
